Mutant forms of cholera holotoxin as an adjuvant

US7285281B2 · kind B2 · utility

Assignees

• Wyeth, LLC · US
• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• Bruce A. Green · Pittsford, US
• Randall K. Holmes · Golden, US
• Michael G. Jobling · Aurora, US
• Duzhang Zhu · Pomona, US

Key dates

• Filing date: Jun 5, 2002
• Grant date: Oct 23, 2007
• Expiry date: Dec 31, 2023

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.